Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Yarrow Bioscience, Inc.MNLO · Entity 6871 | Chief Medical Officer | December 10, 2018 | December 12, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Yarrow Bioscience, Inc.
Report date December 10, 2018 · Filed December 12, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.51 · Expires 2028-12-10 | Direct | 96,000 |
Reported balance
After 2018-12-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-12-10 · Grant · Acquired 96,000 · Balance 96,000 F1: The shares subject to the option will vest over a period of four years, with 1/48th of the shares subject to the option vesting monthly. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest over a period of four years, with 1/48th of the shares subject to the option vesting monthly.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2018 Filed Dec 12, 2018 18:43 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Option · Derivative | 96,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001566044-18-000013 · edgardoc.xml · derivative · entry 1 Spellman Mary · CIK 0001740108 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock · 96,000 shares Expires 2028-12-10 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/48th of the shares subject to the option vesting monthly. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.